Pro Tip: Learn how to use HBI Alerts to follow your favorite topics

Switzerland

 

HBI 2026: Why now is the time to invest in DACH

Across Europe, the DACH region stands out for its scale, stability, and potential for consolidation.  At HBI 2026, a panel of senior investors and operators highlighted why the region is increasingly seen as an attractive and underappreciated market for healthcare consolidation.

Novartis sells Indian arm to PE as big pharma pivots to specialty medicines

Global pharma is increasingly viewing emerging markets in three segments, retaining operations hubs and premium specialty markets while exiting older, mass‑market generics. European companies are divesting legacy portfolios to focus on high-growth biologics and precision medicines.

Revenue distribution of top 100 hospital groups in EMEA by country

This week’s infographic aggregates the 2024 total revenues of the top 100 hospital groups across Europe, the Middle East, and Africa, segmented by country, exposing distinct concentrations of market size and investment intensity.  The data has been sourced from the HBI Intelligence database. Germany commands a dominant position with €22.6 billion in hospital revenues, over […]

Affidea expands in Switzerland with Uroviva acquisition

Affidea, a pan-European diagnostics and outpatient group, has acquired Uroviva Group, a Swiss urology network, from German Equity Partners IV, a Frankfurt-based buyout fund managed by ECM Equity Capital Management.

Swiss healthcare financing reform to benefit private outpatient sector

Switzerland has voted to overhaul how its healthcare system is financed. Inpatient and outpatient care will both be financed in the same way from 2028, which should enable private outpatient clinics to compete on a more level playing field with public hospitals, particularly in specialisms which are increasingly done on an outpatient basis, such as ophthalmology.

Find Us